Program
obicetrapib
Also written as “TA-8995”, “Obicetrapib” and “Obicetrapib 10 mg”.
Its studies are mostly in Dyslipidemias · Hypercholesterolemia · Alzheimer Disease · Hyperlipidemias · Atherosclerosis, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| NewAmsterdam Pharma | 197 open or running | phase 3since Nov 18, 2021 | Feb 9, 2021 | Nov 2026phase 2 · NCT06496243 |
| Xention | 60 open or running | phase 2since Oct 21, 2013 | Oct 21, 2013 | none ahead |
| Tanabe Pharma | 20 open or running | phase 1since Jun 4, 2013 | Jun 4, 2013 | none ahead |
Also a collaborator on its studies: pharma-medica-research-inc and novum.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 13 studies since Jun 4, 2013.
- Feb 23, 2022Phase 2 study in DyslipidemiasNewAmsterdam Pharma · NCT05266586 · 119 enrolled · United States
- Jun 13, 2022Phase 2 study in DyslipidemiasNewAmsterdam Pharma · NCT05421078 · 102 enrolled · Japan
- Jun 15, 2022Phase 3 study in DyslipidemiasNewAmsterdam Pharma · NCT05425745 · 354 enrolled · United States, Canada, Czechia and more
- Jul 25, 2023Phase 1 study in Lipid MetabolismNewAmsterdam Pharma · NCT05972278 · 22 enrolled · United States
- Aug 15, 2023Phase 3 study in DyslipidemiasNewAmsterdam Pharma · NCT06005597 · 407 enrolled · United States
- Aug 29, 2023Phase 1 study in Hepatic ImpairmentNewAmsterdam Pharma · NCT06048302 · 18 enrolled · United States
- Oct 3, 2023Phase 1 study in Healthy VolunteersNewAmsterdam Pharma · NCT06081166 · 74 enrolled · Canada
- Feb 1, 2024Phase 1 study in Healthy VolunteersNewAmsterdam Pharma · NCT06250205 · 30 enrolled · United States
- Feb 28, 2024Phase 3 study in HyperlipidemiasNewAmsterdam Pharma · NCT06305559 · 300 enrolled · United States
- Jul 3, 2024Phase 2 study in DyslipidemiasNewAmsterdam Pharma · NCT06496243 · 69 planned · United States
- Aug 1, 2024Phase 1 study in Healthy VolunteersNewAmsterdam Pharma · NCT06547359 · 94 enrolled · Canada
- May 13, 2025Phase 2 study in Antioxidant AbsorptionNewAmsterdam Pharma · NCT06982508 · 100 planned · United States
- Oct 20, 2025Phase 3 study in HyperlipidemiasNewAmsterdam Pharma · NCT07219602 · 300 enrolled · United States, Czechia, Netherlands and more
- Aug 12, 2026Phase 2 study in Alzheimer DiseaseNewAmsterdam Pharma · NCT07794670 · 400 planned · United States
Ahead
- Nov 2026Primary completion: phase 2 study in DyslipidemiasNewAmsterdam Pharma · NCT06496243
- Nov 2026Primary completion: phase 3 study in AtherosclerosisNewAmsterdam Pharma · NCT05202509
- Nov 2027Primary completion: phase 3 study in HyperlipidemiasNewAmsterdam Pharma · NCT06305559
- Mar 2028Primary completion: phase 3 study in HyperlipidemiasNewAmsterdam Pharma · NCT07219602
TargetBeta
“Cholesteryl ester transfer protein inhibitor”ChEMBL 37, by rule
Studies
All 27 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07794670Alzheimer Disease · United States | 2 | Recruiting | NewAmsterdam Pharma | Sep 2028 | 400 |
| NCT07219602Hyperlipidemias · United States, Czechia, Netherlands and more | 3 | Active, not recruiting | NewAmsterdam Pharma | Mar 2028 | 300 |
| NCT06982508Antioxidant Absorption · United States | 2 | Recruiting | NewAmsterdam Pharma | Sep 2026 | 100 |
| NCT06547359Healthy Volunteers · Canada | 1 | Completed | NewAmsterdam Pharma | Nov 12, 2024 | 94 |
| NCT06496243Dyslipidemias · United States | 2 | Recruiting | NewAmsterdam Pharma | Nov 2026 | 69 |
| NCT06305559Hyperlipidemias · United States | 3 | Active, not recruiting | NewAmsterdam Pharma | Nov 2027 | 300 |
| NCT06250205Healthy Volunteers · United States | 1 | Completed | NewAmsterdam Pharma | Apr 25, 2024 | 30 |
| NCT06081166Healthy Volunteers · Canada | 1 | Completed | NewAmsterdam Pharma | Dec 2, 2023 | 74 |
| NCT06048302Hepatic Impairment · United States | 1 | Completed | NewAmsterdam Pharma | Mar 12, 2024 | 18 |
| NCT06005597Dyslipidemias · United States | 3 | Completed | NewAmsterdam Pharma | Sep 25, 2024 | 407 |
| NCT05972278Lipid Metabolism · United States | 1 | Active, not recruiting | NewAmsterdam Pharma | Sep 26, 2024 | 22 |
| NCT05425745Dyslipidemias · United States, Canada, Czechia and more | 3 | Completed | NewAmsterdam Pharma | May 28, 2024 | 354 |
| NCT05421078Dyslipidemias · Japan | 2 | Completed | NewAmsterdam Pharma | Mar 24, 2023 | 102 |
| NCT05266586Dyslipidemias · United States | 2 | Completed | NewAmsterdam Pharma | Aug 12, 2022 | 119 |
| NCT05161715Alzheimer Disease · Netherlands | 2 | Completed | NewAmsterdam Pharma | May 9, 2023 | 13 |
| NCT05202509Atherosclerosis · United States, Australia, Bulgaria and more | 3 | Active, not recruiting | NewAmsterdam Pharma | Nov 2026 | 9,541 |
| NCT05142722Dyslipidemias · United States, China, Czechia and more | 3 | Completed | NewAmsterdam Pharma | Sep 26, 2024 | 2,530 |
| NCT04770389Dyslipidemias · United States, Netherlands | 2 | Completed | NewAmsterdam Pharma | May 7, 2021 | 112 |
| NCT04753606Dyslipidemias · United States | 2 | Completed | NewAmsterdam Pharma | May 24, 2021 | 120 |
| NCT02523391Dyslipidemias · United Kingdom | 1 | Completed | Xention | Nov 2015 | 26 |
| NCT02408055Dyslipidemias · United Kingdom | 1 | Completed | Xention | Aug 2015 | 6 |
| NCT02241772Elevated Lp(a) · Denmark | 2 | Completed | Xention | Jan 2015 | 42 |
| NCT02241759Dyslipidemias · United Kingdom | 1 | Completed | Xention | Nov 2014 | 136 |
| NCT02124954Pharmacokinetic Interactions · United Kingdom | 1 | Completed | Xention | Jul 2014 | 18 |
| NCT01970215Dyslipidemias · Denmark, Netherlands | 2 | Completed | Xention | Jul 2014 | 364 |
| NCT01879020Dyslipidemias · Germany | 1 | Completed | Tanabe Pharma | Jun 2010 | 61 |
| NCT01878474Dyslipidemias · United Kingdom | 1 | Completed | Tanabe Pharma | Jun 2009 | 96 |
How it is read
Names in the registry
- “TA-8995”, 16 entries
- “Obicetrapib”, 11 entries
- “Obicetrapib 10 mg”, 2 entries
- “obicetrapib 10 mg + ezetimibe 10 mg FDC daily”, 2 entries
- “Obicetrapib 10mg”, 2 entries
Conditions, from the studies’ own filings
- Dyslipidemias, 10 studies
- Hypercholesterolemia, 4 studies
- Alzheimer Disease, 2 studies
- Hyperlipidemias, 2 studies
- Atherosclerosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.